Hospital
Ochsner Clinic Foundation
Ochsner Clinic Foundation was paid $166.97M by Medicaid between Jan 2018 and Dec 2024, across 457 billing codes. Its largest line is 99284, emergency room visit (serious) — 29% of everything it billed.
33Billing provider infoOCHSNER CLINIC FOUNDATION
NEW ORLEANS, LA 70121
NEW ORLEANS, LA 70121
33aNPI1811973100assigned 12/19/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$166.97M
24GClaims3,914,418
24DCodes billed457
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Louisiana
Rank by total paid#2 of 96
Median peer was paid$5.17M
This provider vs. median32×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 318,892 | $10.37M | |
| 2019 | 420,148 | $14.57M | |
| 2020 | 402,850 | $16.23M | |
| 2021 | 701,997 | $29.78M | |
| 2022 | 755,594 | $32.58M | |
| 2023 | 762,107 | $35.70M | |
| 2024incomplete | 552,830 | $27.75M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 29% | 227,670 | 209,495 | $48.45M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 13% | 619,805 | 542,046 | $21.27M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 12% | 91,743 | 82,803 | $19.76M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 126,778 | 118,941 | $16.99M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 3.2% | 185,079 | 151,073 | $5.42M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.1% | 93,758 | 55,301 | $5.18M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.1% | 89,607 | 82,729 | $3.57M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.0% | 63,266 | 58,677 | $3.30M |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.6% | 41,638 | 38,277 | $2.61M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 67,220 | 55,639 | $1.86M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 55,837 | 49,909 | $1.66M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 56,075 | 49,869 | $1.64M |
445 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 16,615 | $1.59M |
| 81514 | <1% | 11,391 | $1.50M | |
| 80053 | Comprehensive metabolic panel | <1% | 214,588 | $1.48M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 99,124 | $1.47M |
| G0378 | Hospital observation service, per hour | <1% | 8,628 | $1.46M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 233,728 | $1.17M |
| 81025 | <1% | 147,474 | $951K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 17,091 | $904K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 15,458 | $824K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 32,102 | $820K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 62,625 | $741K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 47,592 | $737K |
| 87481 | <1% | 12,268 | $721K | |
| 59025 | Fetal non-stress test | <1% | 8,024 | $672K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 3,016 | $616K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 30,179 | $595K |
| 93325 | <1% | 8,869 | $583K | |
| 71045 | Radiologic examination, chest; single view | <1% | 33,110 | $579K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 26,254 | $536K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 11,206 | $517K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 3,502 | $508K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 3,450 | $507K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 17,442 | $503K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,685 | $477K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,538 | $435K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 23,286 | $420K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 15,645 | $396K |
| 36415 | Collection of venous blood by venipuncture | <1% | 178,722 | $392K |
| 83880 | <1% | 17,151 | $367K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 11,402 | $362K |
| 20610 | <1% | 4,989 | $357K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 24,534 | $333K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 3,578 | $326K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 4,668 | $323K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 2,333 | $310K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 11,132 | $309K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 4,321 | $300K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 11,632 | $288K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 11,178 | $285K |
| 84484 | <1% | 36,190 | $267K | |
| 93320 | <1% | 3,427 | $257K | |
| 64615 | <1% | 1,425 | $236K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,044 | $234K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 943 | $230K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 8,156 | $227K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 32,565 | $221K |
| 86803 | <1% | 19,879 | $207K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 9,211 | $185K |
| 76801 | <1% | 2,759 | $184K | |
| 54300 | <1% | 581 | $179K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 9,267 | $178K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,100 | $176K |
| 69210 | <1% | 3,351 | $169K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,655 | $162K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 3,972 | $154K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 2,032 | $150K |
| 0002A | <1% | 4,341 | $138K | |
| 0001A | <1% | 4,211 | $134K | |
| T2101 | Human breast milk processing, storage and distribution only | <1% | 7,903 | $128K |
| 81000 | <1% | 45,690 | $127K | |
| 31575 | <1% | 354 | $126K | |
| 42830 | <1% | 260 | $124K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 8,546 | $123K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 17,788 | $119K |
| 87510 | <1% | 6,429 | $115K | |
| 87660 | <1% | 6,381 | $114K | |
| 87480 | <1% | 6,371 | $114K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 37,365 | $113K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 399 | $112K |
| 93304 | <1% | 1,155 | $104K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,324 | $101K |
| 83690 | <1% | 20,102 | $99K | |
| 80061 | Lipid panel | <1% | 10,705 | $98K |
| 80050 | General health panel | <1% | 2,678 | $97K |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 20 | $94K |
| 95816 | <1% | 682 | $91K | |
| 81003 | <1% | 46,397 | $85K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,859 | $85K |
| 0071A | <1% | 2,197 | $83K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 48,010 | $81K |
| 64642 | <1% | 368 | $81K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 221 | $79K |
| 93321 | <1% | 1,151 | $76K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,416 | $74K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,885 | $72K |
| 86703 | <1% | 6,886 | $72K | |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 325 | $71K |
| 0072A | <1% | 1,714 | $68K | |
| 94010 | <1% | 1,292 | $68K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 80 | $68K |
| 92579 | <1% | 2,568 | $66K | |
| 80074 | <1% | 2,059 | $62K | |
| 92134 | <1% | 3,463 | $58K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 2,141 | $58K |
| 91200 | <1% | 391 | $57K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,748 | $56K |
| 92060 | <1% | 3,613 | $54K | |
| 83735 | <1% | 15,352 | $53K | |
| 87081 | <1% | 7,922 | $51K | |
| 87634 | <1% | 796 | $48K | |
| 86003 | <1% | 1,452 | $47K | |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 53 | $43K |
| 94618 | <1% | 799 | $40K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 819 | $40K |
| 92567 | <1% | 4,304 | $39K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 2,458 | $39K |
| 95800 | <1% | 274 | $37K | |
| 81002 | <1% | 12,356 | $37K | |
| J3490 | Unclassified drugs | <1% | 8,662 | $36K |
| 93296 | <1% | 4,548 | $36K | |
| 87522 | Neg quan hep c or qual rna | <1% | 970 | $35K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 217 | $35K |
| 51798 | <1% | 527 | $35K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 79 | $35K |
| 97162 | <1% | 1,044 | $35K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 216 | $34K |
| 82962 | <1% | 14,075 | $34K | |
| 92523 | <1% | 302 | $30K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 322 | $30K |
| 81001 | <1% | 12,246 | $27K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 544 | $27K |
| 76830 | Ultrasound, transvaginal | <1% | 562 | $27K |
| 94729 | <1% | 822 | $26K | |
| 73630 | <1% | 1,097 | $26K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 72 | $25K |
| 86592 | <1% | 7,069 | $24K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 526 | $24K |
| 0004A | <1% | 654 | $23K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 286 | $23K |
| 85610 | <1% | 8,721 | $21K | |
| 84439 | <1% | 2,988 | $21K | |
| 87400 | <1% | 2,765 | $21K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 38 | $20K |
| 95012 | <1% | 738 | $20K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 513 | $20K |
| 74018 | <1% | 713 | $20K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,861 | $20K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 21,568 | $20K |
| 73610 | <1% | 793 | $19K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,388 | $18K |
| 11043 | <1% | 110 | $18K | |
| 97166 | <1% | 573 | $18K | |
| 72082 | <1% | 248 | $18K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,087 | $17K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 254 | $17K |
| 86900 | <1% | 2,192 | $16K | |
| 87340 | <1% | 2,002 | $16K | |
| 84702 | <1% | 1,209 | $16K | |
| 0011A | <1% | 482 | $15K | |
| 92587 | <1% | 151 | $15K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 4,896 | $15K |
| 96367 | <1% | 702 | $15K | |
| 92133 | <1% | 318 | $15K | |
| 96416 | <1% | 155 | $15K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 14,479 | $14K |
| 86769 | <1% | 930 | $14K | |
| 0012A | <1% | 449 | $14K | |
| 94761 | <1% | 1,393 | $14K | |
| 86850 | <1% | 1,940 | $14K | |
| 86762 | <1% | 1,399 | $14K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,138 | $14K |
| 73564 | <1% | 292 | $14K | |
| 94727 | <1% | 283 | $14K | |
| 90686 | <1% | 2,038 | $13K | |
| 85045 | <1% | 4,030 | $13K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 29 | $13K |
| 85027 | <1% | 3,804 | $13K | |
| 82728 | <1% | 1,348 | $13K | |
| 87088 | <1% | 2,041 | $13K | |
| 87186 | <1% | 2,002 | $13K | |
| 86140 | <1% | 3,811 | $13K | |
| 92610 | <1% | 419 | $12K | |
| 87077 | <1% | 2,025 | $12K | |
| 31231 | <1% | 27 | $12K | |
| 82977 | <1% | 1,850 | $11K | |
| 90715 | <1% | 772 | $11K | |
| 96376 | <1% | 1,068 | $11K | |
| 54161 | <1% | 633 | $11K | |
| 83655 | <1% | 886 | $10K | |
| 73110 | <1% | 288 | $10K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 211 | $10K |
| 93298 | <1% | 678 | $10K | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 135 | $10K |
| 94060 | <1% | 161 | $10K | |
| 93242 | <1% | 135 | $10K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 238 | $9K |
| 95886 | <1% | 405 | $9K | |
| 0003A | <1% | 247 | $9K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 39 | $9K |
| 97161 | <1% | 141 | $8K | |
| 82105 | <1% | 900 | $8K | |
| 86901 | <1% | 2,243 | $8K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 61 | $8K |
| 01922 | <1% | 25 | $8K | |
| 97803 | <1% | 882 | $8K | |
| 93299 | <1% | 522 | $8K | |
| 86593 | <1% | 2,038 | $8K | |
| 54360 | <1% | 127 | $8K | |
| 73562 | <1% | 285 | $8K | |
| 80197 | <1% | 1,386 | $7K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,715 | $7K |
| 77072 | <1% | 280 | $7K | |
| 84466 | <1% | 751 | $7K | |
| 82784 | <1% | 817 | $7K | |
| 73521 | <1% | 147 | $6K | |
| 91321 | <1% | 202 | $6K | |
| 76820 | <1% | 90 | $6K | |
| 87807 | <1% | 472 | $6K | |
| 92511 | <1% | 93 | $6K | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 21 | $6K |
| 73130 | <1% | 247 | $6K | |
| 97802 | <1% | 1,375 | $6K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 82 | $6K |
| 72100 | <1% | 192 | $6K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 512 | $6K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 391 | $5K |
| 97165 | <1% | 154 | $5K | |
| 84100 | <1% | 2,155 | $5K | |
| 0064A | <1% | 171 | $5K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 72 | $5K |
| J2704 | Injection, propofol, 10 mg | <1% | 13,932 | $5K |
| 96113 | <1% | 429 | $5K | |
| 87210 | <1% | 1,149 | $5K | |
| J7318 | Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg | <1% | 14 | $5K |
| 82607 | <1% | 536 | $5K | |
| 80076 | <1% | 690 | $5K | |
| 80055 | <1% | 242 | $5K | |
| 80047 | <1% | 623 | $5K | |
| 92083 | <1% | 163 | $5K | |
| 96112 | <1% | 527 | $5K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 26 | $4K |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 1,197 | $4K |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 197 | $4K |
| 82150 | <1% | 837 | $4K | |
| 92557 | <1% | 108 | $4K | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 122 | $4K |
| 83615 | <1% | 1,186 | $4K | |
| 83605 | <1% | 528 | $4K | |
| 57454 | <1% | 13 | $4K | |
| 83540 | <1% | 810 | $4K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 7,221 | $3K |
| 82950 | <1% | 769 | $3K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 81 | $3K |
| 73100 | <1% | 111 | $3K | |
| C1769 | Guide wire | <1% | 50 | $3K |
| 76770 | <1% | 30 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 12,019 | $3K |
| 92285 | <1% | 289 | $3K | |
| 83516 | <1% | 283 | $3K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 102 | $3K |
| M0220 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring | <1% | 27 | $3K |
| 64643 | <1% | 148 | $3K | |
| 11750 | <1% | 14 | $3K | |
| 62323 | <1% | 24 | $3K | |
| V2632 | Posterior chamber intraocular lens | <1% | 30 | $3K |
| 85652 | <1% | 1,520 | $3K | |
| 86364 | <1% | 453 | $3K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 34 | $3K |
| 82785 | <1% | 206 | $3K | |
| 31579 | <1% | 14 | $3K | |
| 82803 | <1% | 602 | $3K | |
| 11765 | <1% | 19 | $3K | |
| 82570 | <1% | 774 | $3K | |
| 82378 | <1% | 174 | $3K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 20 | $2K |
| 0352U | <1% | 821 | $2K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 118 | $2K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,500 | $2K |
| 95913 | <1% | 26 | $2K | |
| 85379 | <1% | 307 | $2K | |
| 85018 | <1% | 961 | $2K | |
| 90661 | <1% | 302 | $2K | |
| 86787 | <1% | 195 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,337 | $2K |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 394 | $2K |
| 92201 | <1% | 114 | $2K | |
| 82746 | <1% | 167 | $2K | |
| 0031A | <1% | 82 | $2K | |
| 74019 | <1% | 55 | $2K | |
| 87653 | <1% | 54 | $2K | |
| 80069 | <1% | 746 | $2K | |
| 0124A | <1% | 94 | $2K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 24 | $2K |
| 83021 | <1% | 109 | $2K | |
| 87070 | <1% | 253 | $2K | |
| 0054A | <1% | 49 | $2K | |
| 90656 | <1% | 408 | $2K | |
| 87486 | <1% | 58 | $2K | |
| 87581 | <1% | 58 | $2K | |
| 86317 | <1% | 52 | $2K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,208 | $2K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,134 | $2K |
| 83020 | <1% | 158 | $2K | |
| 11721 | <1% | 165 | $1K | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 207 | $1K |
| 82248 | <1% | 478 | $1K | |
| 86704 | <1% | 125 | $1K | |
| 86790 | <1% | 109 | $1K | |
| 80320 | <1% | 123 | $1K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 60 | $1K |
| 86334 | <1% | 127 | $1K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 17 | $1K |
| 77014 | <1% | 36 | $1K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 174 | $1K |
| 97602 | <1% | 18 | $1K | |
| 90480 | <1% | 293 | $1K | |
| 85660 | <1% | 279 | $1K | |
| 20550 | <1% | 12 | $1K | |
| 93356 | <1% | 13 | $1K | |
| 83521 | <1% | 174 | $1K | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 983 | $1K |
| 82330 | <1% | 111 | $1K | |
| 86706 | <1% | 109 | $989.25 | |
| 90677 | <1% | 28 | $989.19 | |
| 96401 | <1% | 30 | $955.81 | |
| 86258 | <1% | 144 | $929.56 | |
| 93017 | <1% | 13 | $903.00 | |
| 11730 | <1% | 15 | $804.25 | |
| 92226 | <1% | 162 | $802.73 | |
| 83993 | <1% | 44 | $757.29 | |
| 72040 | <1% | 26 | $745.27 | |
| 94726 | <1% | 12 | $735.17 | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 1,514 | $727.95 |
| 83520 | <1% | 114 | $708.89 | |
| 95819 | <1% | 14 | $708.40 | |
| 73030 | <1% | 27 | $680.57 | |
| 85651 | <1% | 293 | $679.37 | |
| 99459 | <1% | 1,071 | $677.04 | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 12 | $667.58 |
| 84134 | <1% | 260 | $663.23 | |
| 82040 | <1% | 198 | $661.18 | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 14 | $651.90 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,635 | $642.35 |
| 93990 | <1% | 100 | $636.65 | |
| 93970 | <1% | 14 | $618.12 | |
| 84165 | <1% | 127 | $605.97 | |
| 96417 | <1% | 18 | $595.23 | |
| 72110 | <1% | 46 | $529.61 | |
| 72081 | <1% | 12 | $510.10 | |
| 91320 | <1% | 33 | $497.27 | |
| Q3014 | Telehealth originating site facility fee | <1% | 181 | $476.60 |
| 96127 | <1% | 176 | $473.94 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 121 | $451.79 |
| 92604 | <1% | 16 | $448.39 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 43 | $437.75 |
| 83001 | <1% | 28 | $434.77 | |
| 86696 | <1% | 26 | $433.86 | |
| 84144 | <1% | 35 | $425.71 | |
| 82550 | <1% | 91 | $423.70 | |
| 84156 | <1% | 136 | $417.21 | |
| 82565 | <1% | 130 | $375.26 | |
| 84403 | <1% | 14 | $368.83 | |
| 84402 | <1% | 14 | $363.95 | |
| 82043 | <1% | 113 | $349.78 | |
| 96111 | <1% | 15 | $343.38 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 195 | $338.06 |
| 91305 | <1% | 134 | $333.58 | |
| 84132 | <1% | 115 | $326.75 | |
| 90714 | <1% | 56 | $326.56 | |
| 86694 | <1% | 26 | $322.64 | |
| 0053A | <1% | 17 | $298.30 | |
| 76818 | <1% | 15 | $296.88 | |
| 86695 | <1% | 26 | $295.70 | |
| 84295 | <1% | 99 | $289.30 | |
| 90732 | <1% | 16 | $279.67 | |
| C1729 | Catheter, drainage | <1% | 19 | $273.23 |
| 87147 | <1% | 71 | $267.92 | |
| 83002 | <1% | 14 | $264.67 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 177 | $256.11 |
| 73590 | <1% | 14 | $253.56 | |
| 86300 | <1% | 13 | $253.50 | |
| 91307 | <1% | 3,916 | $250.22 | |
| 80329 | <1% | 29 | $223.44 | |
| 82274 | <1% | 13 | $214.67 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 6,718 | $203.38 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 206 | $198.64 |
| 88142 | <1% | 12 | $194.28 | |
| 0052A | <1% | 34 | $186.12 | |
| 82805 | <1% | 19 | $178.46 | |
| A4550 | Surgical trays | <1% | 31 | $175.23 |
| 85730 | <1% | 53 | $171.15 | |
| 94760 | <1% | 78 | $168.28 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 2,543 | $161.14 |
| 84153 | <1% | 12 | $130.57 | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 14 | $120.01 |
| 85014 | <1% | 117 | $115.72 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,371 | $114.84 |
| 87040 | <1% | 21 | $114.35 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 20 | $111.66 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 322 | $109.55 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 67 | $104.15 |
| 99490 | Ccm add 20min | <1% | 219 | $103.28 |
| 84480 | <1% | 12 | $102.08 | |
| 83525 | <1% | 14 | $93.26 | |
| 97810 | <1% | 107 | $92.50 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 252 | $84.92 |
| 85347 | <1% | 17 | $81.41 | |
| 97811 | <1% | 103 | $77.10 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,181 | $74.46 |
| 91300 | <1% | 8,911 | $63.02 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 365 | $58.79 |
| 84550 | <1% | 26 | $49.99 | |
| 99497 | <1% | 36 | $44.32 | |
| 84460 | <1% | 15 | $43.98 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 13 | $43.50 |
| 84425 | <1% | 24 | $43.04 | |
| 84075 | <1% | 16 | $42.96 | |
| 82947 | <1% | 15 | $39.54 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 309 | $39.53 |
| 88720 | <1% | 15 | $37.67 | |
| 84450 | <1% | 15 | $37.62 | |
| 85007 | <1% | 25 | $36.45 | |
| 82247 | <1% | 15 | $35.17 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 56 | $34.52 |
| 96380 | <1% | 12 | $31.02 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 12 | $27.13 |
| 84155 | <1% | 15 | $26.65 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 163 | $6.51 |
| 91312 | <1% | 116 | $0.34 | |
| 91306 | 0% | 145 | $0.00 | |
| 55175 | 0% | 674 | $0.00 | |
| 00126 | 0% | 387 | $0.00 | |
| 81511 | 0% | 84 | $0.00 | |
| 91301 | 0% | 830 | $0.00 | |
| Q0222 | Injection, bebtelovimab, 175 mg | 0% | 22 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 52 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 15 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 22 | $0.00 |
| 91303 | 0% | 60 | $0.00 | |
| 82657 | 0% | 12 | $0.00 | |
| J1597 | Injection, glycopyrrolate (glyrx-pf), 0.1 mg | 0% | 16 | $0.00 |
| 00731 | 0% | 31 | $0.00 | |
| 00920 | 0% | 585 | $0.00 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 614 | $0.00 |
| 95874 | 0% | 27 | $0.00 | |
| Q0220 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg | 0% | 26 | $0.00 |
| J0290 | Injection, ampicillin sodium, 500 mg | 0% | 23 | $0.00 |
| 76942 | 0% | 15 | $0.00 | |
| 87075 | 0% | 14 | $0.00 | |
| 90662 | 0% | 12 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 28 | $0.00 |
| 11056 | 0% | 12 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 34 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 14 | $0.00 |
| Q0239 | Injection, bamlanivimab-xxxx, 700 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialNOVEMBER, PETER (EVP AND CFO)
Parent organizationOCHSNER MEDICAL CENTER
| Provider | Location | Paid |
|---|---|---|
| Ochsner Medical Center - Kenner, L.L.C. | Kenner, LA | $25.00M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.